# **ORIGINAL ARTICLE**



# Oxachelin, a Novel Iron Chelator and Antifungal Agent from *Streptomyces* sp. GW9/1258

Bernd Sontag, Martin Gerlitz, Thomas Paululat, Hans-Falk Rasser, Iris Grün-Wollny, Friedrich G. Hansske

Received: June 20, 2006 / Accepted: October 10, 2006 © Japan Antibiotics Research Association

**Abstract** During a screening campaign for new antimicrobial and antifungal secondary metabolites from several thousand actinomycetes, a novel compound, isolated by activity guided fractionation, was oxachelin (1) from the new *Streptomyces* sp. GW9/1258. Oxachelin shows strong antibiotic activities against several fungi and Gram(+) bacteria. Additionally, oxachelin is a strong complexing ligand for Fe<sup>3+</sup> (siderophore), possibly making it useful *e.g.* for iron excess diseases.

**Keywords** oxachelin, antifungal agents, iron chelator, *Streptomyces*, microbial products

## Introduction

Iron in form of its cations  $Fe^{2+}$  and  $Fe^{3+}$  plays a pivotal role in many biological systems, and iron deficiency diseases are prevalent especially in developing countries, but also in industrialized regions. On the other hand, an excess of iron causes severe damages and plays a pivotal role in diseases like Friedreich's ataxy [1], cardiomyopathy [2], aplastic anemia [3], thalassemia [4], hepatitis [5], Parkinson's Disease (PD) [6], Alzheimer's Disease (AD) [7] or amyotrophic lateral sclerosis (ALS) [8]. Therefore, it is essential to develop new drugs which are able to modulate the iron resorption, distribution and excretion in humans. With the siderophore oxachelin (1) we isolated a new natural product which may be useful as a lead structure for the treatment of above mentioned diseases.

B. Sontag (Corresponding author), H.-F. Rasser, I. Grün-Wollny, F. G. Hansske: BioFocus DPI GmbH, Waldhofer Str. 104, D-69123 Heidelberg, Germany E-mail: bernd.sontag@glpg.com Siderophores are widely known from natural sources, especially from soil bacteria which are using those molecules to assimilate and transport  $Fe^{3+}$ . A broadly used iron chelator is deferoxamine (desferrioxamine, desferrin), originally isolated from *Streptomyces pilosus* [9~11] and now used as its mesylate salt (Desferal<sup>®</sup>) for several iron-related diseases. Structurally closely related are maduraferrin and the madurastatins from *Actinomadura madurae* [12, 13].

# **Materials and Methods**

#### General

Nuclear magnetic resonance spectra (NMR) were measured on a Bruker Avance DRX 500 MHz spectrometer with the solvent signals as internal standard. Analytical HPLC examinations were run on a Waters Millennium system with two independent pumps (Model 590) and a PDA 996 photodiode array detector, using a acetonitril-water gradient on a Chromolith SpeedROD C-18e column (Merck, Darmstadt). Ultraviolet-visible (UV-VIS) spectra were taken directly from the analytical HPLC-PDA runs and show relative intensities. Size exclusion chromatography was conducted on Kronlab glass columns  $(2.5 \times 100 \text{ cm})$  with Sephadex<sup>®</sup> LH-20 (Amersham Biosciences) as column material and methanol as eluent. High resolution mass spectra were run on a Micromass LCT with a TOF detector, combined with a Hewlett-Packard 1100 analytical HPLC.

M. Gerlitz: Sanofi-Aventis, Natural Products Research, Industriepark Höchst, D-65926 Frankfurt/Main, Germany
T. Paululat: University of Siegen, FB8/OC-II, Adolf-Reichwein-Str. 2, D-57068 Siegen, Germany

#### Microorganism

The producing strain GW9/1258 was identified as a new *Streptomyces* sp. (personal communication Prof. Dr. Reiner M. Kroppenstedt, DSMZ, Braunschweig, Germany) and deposited in the strain collection of the laboratory of soil microbiology *Labor Gruen-Wollny*, Giessen, Germany. The microorganism can be cultivated on standard cultivation media like YMG medium.

## Fermentation

Strain GW9/1258 was grown for 7 days at  $27^{\circ}$ C in  $4 \times 1$  liter shaking flasks each containing 250 ml of YMG medium: 4 g glucose, 4 g yeast extract and 10 g malt extract in one liter of deionized water, pH adjusted to 6.5 to 7 before sterilization.

## **Results and Discussion**


#### Isolation

The whole culture broth (1 liter) was evaporated to dryness under reduced pressure at 40°C and the resulting solid was extracted four times with 150 ml methanol. After removal of the solvent, 500 mg of the resulting thick oily gum (5.5 g in total) were separated into fractions by preparative HPLC (column  $4 \times 25$  cm) using a water - acetonitrile gradient on reversed-phase C18. The most active fraction (tested against *Staphylococcus aureus*) was further purified on Sephadex LH-20 (column  $2.5 \times 100$  cm) with methanol as eluent. The activity was tested again and the most active fractions were combined and evaporated to dryness, which resulted in 10 mg oxachelin (1) in form of a white fluffy powder. This material was subsequently used for structure elucidation.

#### **Structure Elucidation**

Oxachelin (1) is a polar substance which is very soluble in DMSO (>50 mg/ml), less soluble in water and methanol and very poorly in chloroform or ethyl acetate. It shows a  $[M-H]^-$  peak at m/z=634 in the (-)ESI-MS, a  $[M+H]^+$  peak at m/z=636 and a  $[M+Na]^+$  peak at m/z=658 in the (+)ESI-MS, corresponding to a molecular mass of 635 Da. Additionally, there is sometimes an accompanying signal observable at m/z=689 with varying intensities, pointing to the formation of a  $[M-2H+Fe^{3+}]^+$  peak. This finding was a first hint to the iron complexing properties of 1. The HR-EI mass spectrum shows a molecular formula of  $C_{27}H_{37}N_7O_{11}$ , which is in good accordance with the elemental analysis (C 50.77, H 5.85, N 15.50).

An H/D exchange experiment analyzed by (+/-)ESI-



**Fig. 1** Qualitative UV-spectrum of oxachelin in acetonitrile/water 2 : 1.

MS using the direct injection mode revealed the presence of 8 exchangeable protons.

The UV-spectrum of **1** (Fig. 1) is not very characteristic, nevertheless pointing to a substituted aromatic system with  $\lambda_{max}$ =203, 245, 249, 255 (sh) and 304 nm.

In the <sup>1</sup>H NMR of 1, there are visible several characteristic signals. Typical for an oxygen-substituted aromatic ABCD-spin system are the four signals at  $\delta_{\scriptscriptstyle \rm H}$  6.93 (t), 6.99 (d), 7.45 (t) and 7.63 (d), with  $\delta_{\rm C}$  119.07, 116.61, 134.00 and 128.07, respectively. In the range of  $7.85 \sim$ 8.24 ppm, there are observable the typically broad signals of 4 CO-NH-protons, showing no correlation to a carbon atom in the gHSQC and suggesting a peptide core structure. In correspondence to this, there are 4  $\alpha$ -CH visible at  $\delta_{\rm H}$  4.17 (attached to a carbon atom which is split into two signals at  $\delta_{\rm C}$ =52.40+52.60), 4.29 ( $\delta_{\rm C}$  49.42), 4.36 ( $\delta_{\rm C}$  55.32) and 5.06 ( $\delta_{\rm C}$  67.24). Interestingly, there are four more carbon signals at  $\delta_{\rm C}$  22.50+22.52, 28.50+28.55, 46.00+48.77, 157.00+161.74 which are also observed as "doublets", indicating the presence of two rotamers. All those "split" carbon atoms can be assigned to a N5hydroxy-N5-formyl-ornithine side-chain, where the splitting of the signals is explained by the presence of two relatively stable conformations generated by the rotation of the formyl-group. At higher temperatures, these signals show coalescence and are observed as broad singlets. This phenomenon is well known from substances with similar structural features like formobactin from Nocardia sp. [14], brasilibactin A from N. brasiliensis [15] or the nocardimicins from N. nova [16, 17].

Taking together the information from 1D and 2D NMR experiments (gCOSY, gTOCSY and gHSQC-TOCSY), the partial structures shown in Fig. 2 can be defined:

The above mentioned partial structures were assembled to the final structure of oxachelin (1) using the information received from <sup>1</sup>H, <sup>13</sup>C-gHMBC, <sup>1</sup>H, <sup>15</sup>N-gHMBC and

Position	$\delta_{ ext{C}}$		$\delta_{\rm H}$ (J Hz)		
1	109.33 s		_		
2	159.07 s				
3	116.61 d		6.99 (d 8.4)		
4	134.00 d	134.00 d 7.45 (ddd 8.4, 7.4, 1.5)		4, 7.4, 1.5)	
5	119.07 d		6.93 (t 7.4)		
6	128.07 d		7.63 (dd 7.4	, 1.5)	
7	166.07 s				
8	—		—		
9	67.24 d		5.06 (dd 10.4	4, 7.7)	
10	69.59 t		4.48 (dd 8.7, 7.7)		
			4.63 (dd 10.4	4, 8.7)	
11	—		—		
12	169.09 s		—		
13	—		8.24 (s br.)		
14	55.32 d		4.36 (m)		
15	169.35 s		_		
16	—		8.10 (d 8.4)		
17	52.4 d	[52.6 d] <sup>a</sup>	4.17 (m)		
18	171.12 s		—		
19	—		7.89 (m)		
			7.95 (m)		
20	35.38 t		3.22 (m)		
21	35.22 t		2.23 (t 7.3)		
22	169.98 s		—		
23	—		8.13 (d 8.4)		
24	49.42 d		4.29 (m)		
25	164.90 s		_		
26-OH	—		9.70 (s)		
27	51.20 t		3.44 (m)		
28	20.25 t		1.84 (m)		
29	26.63 t		1.59 (m)		
			1.86 (m)		
30	61.72 t		3.62 (dd 5.4)		
30-OH			4.98 (s br.)		
31		[28.55 t] <sup>a</sup>	1.44 (m)	[1.64 (m)] <sup>a</sup>	
32		[22.52 t] <sup>a</sup>	1.46 (m)	[1.54 (m)] <sup>a</sup>	
33	46.00 t	[48.77 t] <sup>a</sup>	3.32 (m)	[3.37 (m)]ª	
34-OH			9.70 (s)		
35	157.00 d	[161.74 d] <sup>a</sup>	7.85 (s br.)	[8.21 (s br.)] <sup>a</sup>	

Table 1NMRdataofoxachelin(1)inDMSO-d\_6(500/125 MHz)

<sup>a</sup> Duplicate signals due to rotamers.

ROESY experiments. Hence, oxachelin is a new member of the siderophore family isolated from actinomycetes. A possible biosynthesis of **1** starts from a pentapeptide core structure, to which a salicylic acid is subsequently added and then further modified by hydroxylation, formylation and cyclization.

Besides the above mentioned siderophores formobactin, brasilibactin A and the nocardimicins, there are several more natural products which are structurally very closely related to oxachelin. The characteristic chromophore of 1 formed by the phenol-dihydrooxazole moiety are also present in brasilibactin A, the nocardimicins, antibiotic BE 32030 from Nocardia sp. [18], antibiotic BMS 199687 from Actinomadura ferruginea [19], the mycobactins from Mycobacterium species [20], acinetobactin from Acinetobacter baumannii [21], the anachelins from the cycnobacterium Anabaena cylindrica [22], or antibiotic L654040 from Streptoverticillium syroense [23]. The Nhydroxy-N-formyl side chain is described for example in formobactin, brasilibactin A, the nocardimicins or asterobactin from N. asteroides [24]. A cyclic and hydroxylated form of ornithine or lysine is observed in exochelin MN from M. neoaurum [25], Coelichelin from Streptomyces coelicolor [26] or again formobactin, brasilibactin A, the nocardimicins, the mycobactins, antibiotic BE 32030, antibiotic BMS 199687 or antibiotic L 654040.


#### **Metal Complexing Properties**

To investigate qualitatively the metal complexing properties of oxachelin, 200  $\mu$ l of different metal salt solutions  $(150 \,\mu\text{M})$  were added to 200  $\mu$ l of a solution of 1 (300  $\mu$ M) in deionized water, and the resulting mixture was subsequently analyzed by HPLC. In the case of a complex formation between oxachelin an the metal ion, an approximatly 50% reduction of free 1 is observed compared to non-complexing cations, indicating an equimolar complexation mechanism. Concurrently, complex formation is revealed in the HPLC chromatogram by the formation of a new peak, possessing a higher polarity and a UV spectrum with a bathochromic shift compared to uncomplexed 1. Using this methodology, a 1 : 1 complex formation of oxachelin with  $Fe^{3+}$ ,  $Fe^{2+}$ ,  $Co^{2+}$ , Al<sup>3+</sup>, Cr<sup>3+</sup>, Ni<sup>2+</sup> and Cu<sup>2+</sup> could be shown, whereas Mg<sup>2+</sup>,  $Mn^{2+}$ ,  $Ca^{2+}$ ,  $Ni^{2+}$  or  $Zn^{2+}$  are not complexed by 1. The strong iron complexing properties of 1 are also expressed by the fact, that  $Fe^{3+}$  is removed from  $Fe(SCN)_3$  and also from deferoxamine-Fe (Desferal®-bound iron III) by oxachelin, but not from  $K_3[Fe(CN)_6]$ . On the other hand,  $Fe^{3+}$  cannot be removed from the complex with 1 by addition of  $CN^-$  or  $H_2S$ .

#### **Biological Activities**

Oxachelin was screened against different pathogenic fungi in the microdilution assay with concentrations of  $125 \text{ ng/ml} \sim 125 \mu \text{g/ml}$ :

In the agar diffusion assay, oxachelin shows considerable



**Fig. 2** Partial structures of **1** derived from gCOSY, gTOCSY and gHSQC-TOCSY experiments (DMSO-*d*<sub>6</sub>, 500/125 MHz). Numbering according to Table 1 and Fig. 3.




Fig. 3 Structure of oxachelin (1).




Fig. 4 Indicative <sup>1</sup>H, <sup>13</sup>C-gHMBC ( $\rightarrow$ ), <sup>1</sup>H, <sup>15</sup>N-gHMBC ( $\rightarrow$ ) and ROESY ( $\leftrightarrow$ ) correlations in **1** (DMSO- $d_{6}$ , 500/125/50 MHz).

activity against *Staphylococcus aureus* ATCC 6538. Here, an inhibition zone of 12 mm in diameter is observed (filter disc i.d. 6 mm, c=1 mg/ml, 20  $\mu$ l/disc).

Oxachelin shows no cytotoxicity in the tumor cell lines MCF-7 (ATCC HTB-22), L-929 (DSMZ ACC 2) or HEP-G2 (ATCC HB-8065) in concentrations up to  $80 \,\mu$ M.

## Discussion

Oxachelin (1) represents a novel natural product siderophore isolated from *Streptomyces* sp. GW9/1258, possessing selective metal complexing properties. Especially iron III is strongly bound, making 1 potentially valuable for the therapy of iron overload diseases like thalassemia, hepatitis or Parkinson's disease. Additionally, strong and selective antifungal and antibacterial effects

## Table 2 Antimicrobial spectrum of 1

Fungal species	${ m MIC}_{50}$ ( $\mu{ m M}$ )	МІС <sub>90</sub> (μМ)
Candida albicans ATCC 90028	12	>200
Candida glabrata DSM 6425	6	50
Cryptococcus neoformans ATCC 90112	1.6	3
Rhizomucor pusillus ATCC 36606	12	24
Fusarium solani CBS 181.29	>200	>200
Aspergillus fumigatus HD 3482/01*	50	200
A. flavus HD 2026/01*	100	>200
Trichophyton rubrum EF-S-714*	3	6
Microsporum canis EF-S-713*	3	6

\* Clinical isolates Prof. Dr. med. Reinhard Kappe, Labor Diagnostika GmbH, Erfurt, Germany. could be shown, whilst no cytotoxicity was observed.

Acknowledgements The authors wish to thank Prof. Dr. med. Reinhard Kappe, Labor Diagnostika GmbH, Erfurt, Germany, for carrying out the assays with the pathogenic microorganisms and Dr. Jens Fuchser, Bruker Daltonik GmbH, Bremen, Germany, for high-resolution FT-ICR-MS measurements.

# References

- Seznec H, Simon D, Bouton C, Reutenauer L, Hertzog A, Golik P, Procaccio V, Patel M, Drapier J-C, Koenig M, Puccio H. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet 14: 463–474 (2005)
- Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca<sup>2+</sup> channels in iron transport and iron-overload cardiomyopathy. J Mol Med 84: 349–364 (2006)
- Afanas'ev IB. Superoxide and nitric oxide in pathological conditions associated with iron overload: the effects of antioxidants and chelators. Curr Med Chem 12: 2731–2739 (2005)
- 4. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739–761 (1997)
- Kato J, Kobune M, Kohgo Y, Sugawara N, Hisai H, Nakamura T, Sakamaki S, Sawada N, Niitsu Y. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in long-evans cinnamon rats. J Clin Invest 98: 923–929 (1996)
- Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity *in vivo*: a novel therapy for Parkinson's disease. Neuron 37: 899–909 (2003)
- Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406: 189–193 (2006)
- Yasui M, Ota K, Garruto RM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Neurotoxicology 14: 445–450 (1993)
- Bickel H, Bosshardt R, Gäumann E, Reusser P, Vischer E, Voser W, Wettstein A, Zähner H. Stoffwechselprodukte von Actinomyceten. 26. Mitteilung. Über die Isolierung und Charakterisierung der Ferrioxamine A~F, neuer Wuchsstoffe der Sideramin-Gruppe. Helv Chim Acta 43: 2118–2128 (1960)
- Bickel H, Hall GE, Keller-Schierlein W, Prelog V, Vischer E, Wettstein A. Stoffwechselprodukte von Actinomyceten. 27. Mitteilung. Über die Konstitution von Ferrioxamin B. Helv Chim Acta 43: 2129–2138 (1960)
- Bickel H, Keberle H, Vischer E. Stoffwechselprodukte von Mikroorganismen. 43. Mitteilung. Zur Kenntnis von Desferrioxamin B. Helv Chim Acta 46: 1385–1389 (1963)

- Keller-Schierlein W, Hagmann L, Zähner H, Huhn W. Stoffwechselprodukte von Mikroorganismen. 250. Mitteilung. Maduraferrin, ein neuartiger Siderophor aus *Actinomadura madurae*. Helv Chim Acta 71: 1528–1540 (1988)
- Harada K, Tomida K, Fujii K, Masuda K, Mikami Y, Yazawa K, Komaki H. Isolation and structural characterization of siderophores, madurastatins, produced by a pathogenic *Actinomadura madurae*. J Antibiot 57: 125–135 (2004)
- Murakami Y, Kato S, Nakajima M, Matsuoka M, Kawai H, Shin-Ya K, Seto H. Formobactin, a novel free radical scavenging and neuronal cell protecting substance from *Nocardia* sp. J Antibiot 49: 839–845 (1996)
- Tsuda M, Yamakawa M, Oka S, Tanaka Y, Hoshino Y, Mikami Y, Sato A, Fujiwara H, Ohizumi Y, Kobayashi J. Brasilibactin A, a cytotoxic compound from actinomycete *Nocardia brasiliensis*. J Nat Prod 68: 462–464 (2005)
- Ikeda Y, Nonaka H, Furumai T, Onaka H, Igarashi Y. Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from *Nocardia* sp. TP-A0674. J Nat Prod 68: 1061–1065 (2005)
- Ikeda Y, Furumai T, Igarashi Y. Nocardimicins G, H and I, siderophores with muscarinic M3 receptor binding inhibitory activity from *Nocardia* nova JCM 6044. J Antibiot 58: 566–572 (2005)
- Tsukamoto M, Murooka K, Nakajima S, Abe S, Suzuki H, Hirano K, Kondo H, Kojiri K, Suda H. BE-32030 A, B, C, D and E, new antitumor substances produced by *Nocardia* sp. A32030. J Antibiot 50: 815–821 (1997)
- Tsunakawa M, Chang L, Mamber SW, Bursuker I, Hugill R. (Squibb Bristol Myers & Co.). Antitumor antibiotic BMS-199687. U.S. 5,811,440, September 22 (1998)
- Snow GA. Mycobactins: iron-chelating growth factors from mycobacteria. Bacteriol Rev 34: 99–125 (1970)
- 21. Yamamoto S, Okujo N, Sakakibara Y. Isolation and structure elucidation of acinetobactin, a novel siderophore from *Acinetobacter baumannii*. Arch Microbiol 162: 249–254 (1994)
- 22. Itou Y, Okada S, Murakami M. Two structural isomeric siderophores from the freshwater cyanobacterium *Anabaena cylindrica* (NIES-19). Tetrahedron 57: 9093–9099 (2001)
- Currie SA, Dulaney EL, Miller TW, Springer JP, Valiant ME, Zimmerman SB, Del Val SM (Merck & Co., Inc.). Antibacterial agent. EP 0 332 248, September 13 (1989)
- Nemoto A, Hoshino Y, Yazawa K, Ando A, Mikami Y, Komaki H, Tanaka Y, Grafe U. Asterobactin, a new siderophore group antibiotic from *Nocardia asteroides*. J Antibiot 55: 593–597 (2002)
- 25. Sharman GJ, Williams DH, Ewing DF, Ratledge C. Determination of the structure of exochelin MN, the extracellular siderophore from *Mycobacterium neoaurum*. Chem Biol 2: 553–561 (1995)
- 26. Challis GL, Ravel J. Coelichelin, a new peptide siderophore encoded by the Streptomyces coelicolor genome: structure prediction from the sequence of its non-ribosomal peptide synthetase. FEMS Microbiol Lett 187: 111–114 (2000)